Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

scientific article

Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S00277-008-0600-Y
P698PubMed publication ID18779964
P5875ResearchGate publication ID23245738

P50authorGiovanni PalladiniQ37839091
Giampaolo MerliniQ37839101
Laura ObiciQ56426698
Mario NuvoloneQ56512662
Stefano PerliniQ57005375
P2093author name stringRiccardo Albertini
Vittorio Perfetti
Paola Russo
Remigio Moratti
Francesca Lavatelli
Tiziana Bosoni
P433issue4
P921main subjectthalidomideQ203174
dexamethasoneQ422252
AL amyloidosisQ4652470
P304page(s)347-350
P577publication date2008-09-09
P1433published inAnnals of HematologyQ15766509
P1476titleTreatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide
P478volume88

Reverse relations

cites work (P2860)
Q36862339A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.
Q27023836Amyloid diseases of the heart: current and future therapies
Q33867198Amyloidosis and POEMS syndrome
Q35111771Amyloidosis: pathogenesis and new therapeutic options.
Q42941866An unusual case of IgE-multiple myeloma presenting with systemic amyloidosis 2 years after cervical plasmacytoma resection
Q58030146Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects
Q42177959Cardioverter-defibrillator implantation in myeloma-associated cardiac amyloidosis
Q46695052Clinical features and treatment outcome of primary systemic light-chain amyloidosis in Korea: results of multicenter analysis
Q42662215Current treatment of AL amyloidosis
Q38172998Future directions in the clinical management of amyloid light-chain amyloidosis
Q46400142How to manage primary amyloidosis
Q38970608Immunoglobulin Light Chain Systemic Amyloidosis
Q37832199Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management
Q26827340Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment
Q34448455Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment
Q38928383Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment
Q37212712Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement
Q38072108Light chain amyloidosis 2012: a new era.
Q42958777Light chain amyloidosis: the heart of the problem
Q41593651Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies
Q39024208New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis
Q57904586Primary Systemic Amyloidosis (AL)
Q37328204Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
Q37738576Treatment of immunoglobulin light chain amyloidosis
Q82620976[Amyloidoses]

Search more.